Top

Cellular Oncology

Published in:

01-08-2015 | Report

RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report

Authors: Chuan Zeng, Weidong Fan, Xianquan Zhang

Published in: Cellular Oncology | Issue 4/2015

Abstract

Purpose

RRM1 is the large subunit of ribonucleotide reductase (RNR), which catalyzes the rate-limiting step in the production of deoxyribonucleotides (dNTPs) and is essential for DNA synthesis and repair. Through a meta-analysis of observational studies, we evaluated whether RRM1 expression levels are associated with the clinical outcome of gemcitabine-containing treatment regimens in patients with advanced non-small cell lung cancer (NSCLC).

Methods

A literature search was conducted using the PubMed, Embase, Web of Science, Wanfang and Chinese National Knowledge Infrastructure databases from inception to September 2014. A meta-analysis was conducted to pool eligible studies, and pooled analyses were performed using fixed effects models.

Results

A total of 12 studies encompassing 593 NSCLC patients met our search criteria and were, therefore, included. Pooled analyses revealed that patients with low/negative RRM1 expression levels exhibited significantly higher response rates (OR: 0.35, 95 % CI 0.24–0.51) and better survival rates (OR: 0.41, 95 % CI 0.23–0.75) than those with high/positive RRM1 expression levels. Subgroup analyses did not reveal any significant heterogeneity in outcome regarding the RRM1 assessment methods used or the ethnicities of patient populations studied.

Conclusions

The meta-analysis reported here indicates that RRM1 expression is associated with the response rate and overall survival rate of advanced NSCLC patients treated with gemcitabine-based chemotherapy. Additional phase III randomized trials are required to confirm our current findings.

J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127, 2893–2917 (2008)CrossRef

Q. Wu, Y.F. Chen, J. Fu, Q.H. You, S.M. Wang, X. Huang, X.J. Feng, S.H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell Oncol 37, 399–407 (2014)CrossRef

A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell Oncol 36, 265–75 (2013)CrossRef

N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 36, 277–288 (2013)

R.T. Greenlee, M.B. Hill-Harmon, T. Murray, M. Thun, Cancer statistics. CA Cancer J Clin 5, 15–36 (2001)CrossRef

K. Ohashi, L.V. Sequist, M.E. Arcila, T. Moran, J. Chmielecki, Y.L. Lin, Y. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J.C. Yang, V.A. Miller, G.J. Riely, M.G. Kris, J.A. Engelman, C.L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi, W. Pao, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109, 2127–2133 (2012)

T.K. Owonikoko, M. Behera, Z. Chen, C. Bhimani, W.J. Curran, F.R. Khuri, S.S. Ramalingam, A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 7, 866–872 (2012)PubMedCentralPubMedCrossRef

B. Besse, K.A. Olaussen, J.C. Soria, ERCC1 and RRM1: ready for prime time? J Clin Oncol 31, 1050–1060 (2013)PubMedCrossRef

G. Bepler, M.A. Garcia-Blanco, Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci U S A 91, 5513–5517 (1994)PubMedCentralPubMedCrossRef

10.

G. Bepler, A. Gautam, L.M. McIntyre, A.F. Beck, D.S. Chervinsky, Y.C. Kim, D.M. Pitterle, A. Hyland, Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20, 1353–1360 (2002)PubMedCrossRef

11.

D.M. Pitterle, Y.C. Kim, E.M. Jolicoeur, Y. Cao, K.C. O’Briant, G. Bepler, Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 10, 916–922 (1999)PubMedCrossRef

12.

G.R. Simon, M. Begum, G. Bepler, Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol 4, 51–59 (2008)PubMedCrossRef

13.

J.J. Lee, C.H. Maeng, S.K. Baek, G.Y. Kim, J.H. Yoo, C.W. Choi, Y.H. Kim, Y.T. Kwak, D.H. Kim, Y.K. Lee, J.B. Kim, S.Y. Kim, The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70, 205–210 (2010)PubMedCrossRef

14.

R. Rosell, G. Scagliotti, K.D. Danenberg, R.V. Lord, G. Bepler, S. Novello, J. Cooc, L. Crinò, J.J. Sánchez, M. Taron, C. Boni, F. De Marinis, M. Tonato, M. Marangolo, F. Gozzelino, F. Di Costanzo, M. Rinaldi, D. Salonga, C. Stephens, Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22, 3548–3553 (2003)PubMedCrossRef

15.

J. Souglakos, I. Boukovinas, M. Taron, P. Mendez, D. Mavroudis, M. Tripaki, D. Hatzidaki, A. Koutsopoulos, E. Stathopoulos, V. Georgoulias, R. Rosell, Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98, 1710–1715 (2008)PubMedCentralPubMedCrossRef

16.

C. Su, S. Zhou, L. Zhang, S. Ren, J. Xu, J. Zhang, M. Lv, J. Zhang, C. Zhou, ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 28, 1411–1417 (2011)PubMedCrossRef

17.

A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603–605 (2010)PubMedCrossRef

18.

G. Wells, B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2003. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

19.

Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, G. Bepler, DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356, 800–808 (2007)PubMedCrossRef

20.

W. Gong, X. Zhang, J. Wu, L. Chen, L. Li, J. Sun, Y. Lv, X. Wei, Y. Du, H. Jin, J. Dong, RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 75, 374–380 (2012)PubMedCrossRef

21.

S. Michiels, P. Piedbois, S. Burdett, N. Syz, L. Stewart, J.P. Pignon, Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21, 119–125 (2005)PubMedCrossRef

22.

X. Qin, W. Yao, W. Li, X. Feng, X. Huo, S. Yang, H. Zhao, X. Gu, ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Tumour Biol 35, 4697–4704 (2014)PubMedCrossRef

23.

Y. Yang, L. Xian, The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35, 2905–2921 (2014)PubMedCrossRef

24.

S.H. Lee, K.B. Noh, J.S. Lee, E.J. Lee, K.H. Min, G.Y. Hur, S.H. Lee, S.Y. Lee, J.H. Kim, S.Y. Lee, C. Shin, J.J. Shim, C.H. Kim, K.H. Kang, K.H. In, Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81, 102–108 (2013)PubMedCrossRef

25.

G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, G. Simon, RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non–small-cell lung cancer. J Clin Oncol 24, 4731–4737 (2006)PubMedCrossRef

26.

I. Boukovinas, C. Papadaki, P. Mendez, M. Taron, D. Mavroudis, A. Koutsopoulos, M. Sanchez-Ronco, J.J. Sanchez, M. Trypaki, E. Staphopoulos, V. Georgoulias, R. Rosell, J. Souglakos, Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PloS ONE 3, e3695 (2008)PubMedCentralPubMedCrossRef

27.

Z. Gao, B. Han, J. Shen, A. Gu, H. Zhong, Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients. Chin J Lung Can 14, 340–344 (2011)

28.

B. Jiang, C. Xu, W. He, C. Yang, J. Zhao, Analysis of RRM1 expression and efficacy of gemcitabine in advanced non-small cell lung cancer. Can Res Prev Treat 1, 68–71 (2013)

29.

L. Li, X. Liu, Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer. Bull Acad Mil Med Sci 34(3), 265–268 (2010)

30.

J. Liang, Y. Deng, W. Feng, W. Hu, Z. Chen, Y. Tang, H. Zhang, H. Xian, S. Zhang, The study of the relationship between RRM1 protein expression and the efficacy of gemcitabine-containing regiment for the first-line treatment of advanced non-small cell lung cancer. Guid Chin Med 10, 10–11 (2012)CrossRef

31.

H. Liu, H. Wang, J. Yang, RRM1 expression and efficacy analysis of gemcitabine in advanced non-small cell lung cancer. Pract Prev Med 16, 11–14 (2009)

32.

L. Wang, G. Zhang, J. Chen, J. Li, M. Li, Y. Wang, N. Xu, J.Z. Shen, Effect of RRM1 and BRCA1 expressions on efficiency of gemcitabine and platinum in patients with advanced non-small cell lung cancer. Chin Pharm J 20, 1557–1580 (2010)

Title: RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report
Authors: Chuan Zeng
Weidong Fan
Xianquan Zhang
Publication date: 01-08-2015
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 4/2015
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-015-0225-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP

Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas

Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway

The bone marrow metastasis niche in retinoblastoma

Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid

Keynote webinar | Spotlight on antibody–drug conjugates in cancer